Supplement to Integrated proteomics reveals apoptosis-related mechanisms associated with placental malaria

Supplemental Data

Supplementary Tables S1-S8 - Supplemental Table S1. Evaluation Methods and Staining Used to Quantify Malaria-Associated Placental Parameters. Supplemental Table S2. Baseline Characteristics of both Mothers and Newborns at Delivery. Supplemental Table S3. Placental Parameters of Non-Infected and P. falciparum-infected Pregnant Women. Supplemental Table S4. Protein groups identified in label-free mouse placenta samples. The LFQ intensities was log2 transformed and the T-test was applied in infected and control samples. Reverse and potential contaminants were excluded. Differentially regulated peptides are shown in "+". Proteins identified in P. berghei are highlighted in yellow and were not considered in the total amount of proteins in placenta. MS-viewer search key: rnb08ldiee Supplemental Table S5. Protein groups identified in label-free human placenta samples. The LFQ intensities was log2 transformed and T-test was applied both in the infected and control samples. Reverse and potential contaminants were excluded. Differentially regulated peptides are shown in "+". Proteins identified in P. falciparum are highlighted in yellow and were not considered in the total number of proteins in placenta. MS-viewer search key: jwreohtivy Supplemental Table S6 Significant enriched GO terms for biological process in the dataset from up-regulated proteins identified in human and mouse placentas after infection with Plasmodium sp. Supplemental Table S7. Non-modified peptides identified in TMTlabeled human placenta samples. The reporter ion intensities were log2 transformed and normalized by the mean, and T-test was applied both in the infected and control samples. Reverse and potential contaminants were excluded. Differentially regulated peptides are shown in "+". MS-viewer search key: hwm0mqbx2s Supplemental Table S8. Phosphopeptides and formerly N-glycopeptides identified in TMTlabeled human placenta samples after TiO2 purification and HILIC fractionation. The reporter ion intensities was log2 transformed and normalized by the mean, and the T-test was applied both in the infected and control samples. Reverse and potential contaminants were excluded. Differentially regulated peptides are shown in "+". MS-viewer search key: ipfwhr5osl Supplemental Table S9. Formerly N-glycopeptides identified in TMTlabeled human placenta samples after HILIC purification. The reporter ion intensities was log2 transformed and normalized by mean and T-test was applied both in the infected and control samples. Reverse and potential contaminants were excluded. Differentially regulated peptides are shown in "+". MS-viewer search key: dkscsltllo Supplemental Table S10. Differentially regulated phosphopeptides, glycopeptides and non-modified peptides (T-test, p<0.05). Supplemental Table S11. Significant enriched GO terms for biological process in the dataset from differentially regulated proteins in P. falciparum infected human placentas.
Supplemental Tables S4-S11 - Supplemental Table S4. Protein groups identified in label-free mouse placenta samples. The LFQ intensities was log2 transformed and the T-test was applied in infected and control samples. Reverse and potential contaminants were excluded. Differentially regulated peptides are shown in "+". Proteins identified in P. berghei are highlighted in yellow and were not considered in the total amount of proteins in placenta. MS-viewer search key: rnb08ldiee Supplemental Table S5. Protein groups identified in label-free human placenta samples. The LFQ intensities was log2 transformed and T-test was applied both in the infected and control samples. Reverse and potential contaminants were excluded. Differentially regulated peptides are shown in "+". Proteins identified in P. falciparum are highlighted in yellow and were not considered in the total number of proteins in placenta. MS-viewer search key: jwreohtivy Supplemental Table S6 Significant enriched GO terms for biological process in the dataset from up-regulated proteins identified in human and mouse placentas after infection with Plasmodium sp. Supplemental Table S7. Non-modified peptides identified in TMTlabeled human placenta samples. The reporter ion intensities were log2 transformed and normalized by the mean, and T-test was applied both in the infected and control samples. Reverse and potential contaminants were excluded. Differentially regulated peptides are shown in "+". MS-viewer search key: hwm0mqbx2s Supplemental Table S8. Phosphopeptides and formerly N-glycopeptides identified in TMTlabeled human placenta samples after TiO2 purification and HILIC fractionation. The reporter ion intensities was log2 transformed and normalized by the mean, and the T-test was applied both in the infected and control samples. Reverse and potential contaminants were excluded. Differentially regulated peptides are shown in "+". MS-viewer search key: ipfwhr5osl Supplemental Table S9. Formerly N-glycopeptides identified in TMTlabeled human placenta samples after HILIC purification. The reporter ion intensities was log2 transformed and normalized by mean and T-test was applied both in the infected and control samples. Reverse and potential contaminants were excluded. Differentially regulated peptides are shown in "+". MS-viewer search key: dkscsltllo Supplemental Table S10. Differentially regulated phosphopeptides, glycopeptides and non-modified peptides (T-test, p<0.05). Supplemental Table S11. Significant enriched GO terms for biological process in the dataset from differentially regulated proteins in P. falciparum infected human placentas.
Supplemental Figures S1-S7 - Supplemental Figure 1 Flow chart showing the study design and the criteria of patient selection/exclusion Supplemental Figure 2 Comparison between mouse and human placentas datasets. A) Pearson correlation analysis of mouse and human placentas datasets using log2-IBAQ intensities. B) Normalized log2-IBAQ intensities from all proteins identified in mouse or human datasets were compared in a scatter plot graph. C) Histogram distribution of proteins identified exclusively or shared in mouse and human datasets according to the abundance levels. Supplemental Figure 3. A) Overlapping between the formerly unique N-linked glycosylation sites and (B) N-glycoproteins identified in the human placenta using TiO2 or HILIC enrichment strategy. Supplemental Figure 4. Pearson correlation analysis of TMT-labeled samples. Supplemental Figure 5. Clustering of significant regulated non-modified peptides, phosphopeptides and glycopeptides shown as a heat map after applying the Euclidean distance. Above each heat map, principal component analysis using the set of differentially regulated non-modified peptides, phosphopeptides and glycopeptides. Supplemental Figure 6 A) Number of annotated kinase and phosphatase according to the gene ontology terms for molecular function identified in the phosphoproteome or proteome datasets. String network analysis of the 24-significant enriched predicted kinases by Enrichr (p<0.05). Supplemental Figure 7. Western blotting analysis of HSPB1 phosphorylation at S82, S15 and HSPB1 protein levels in infected and non-infected placentas. α-tubulin was used as loading control and for normalization. The S82 and S15 phospho/total HSPB1 and HSPB1/Tubulin ratio was calculated by densitometry analysis using the ImageJ software (n = 5, Student’s t test *p < 0.05).